Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. Mai 2015 08:30 ET | Quelle: Zogenix, Inc.

Zogenix Announces New Efficacy Data From a Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome

New data presented at European Paediatric Neurology Society Congress in Vienna, Austria includes 10 patients who continued treatment with low-dose fenfluramine for Dravet syndrome following the...
11. Mai 2015 16:01 ET | Quelle: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results

SAN DIEGO, May 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
04. Mai 2015 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11

SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
27. April 2015 16:05 ET | Quelle: Zogenix, Inc.

Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline

SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
24. April 2015 13:00 ET | Quelle: Zogenix, Inc.

Zogenix Closes Sale of Zohydro(R) ER Business to Pernix

SAN DIEGO, April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...

Vorherige Seite